Dr. Hom-Ming Yeh serves as the Associate Director at ARCE Therapeutics, where he leads the development of genetic-engineered cellular immunotherapies and innovative gene delivery techniques. With over a decade of experience in biotechnology and virology, Dr. Yeh specializes in Chimeric Antigen Receptor (CAR) T-cell therapy bio-process development and the manufacturing of pseudotyped lentiviral vectors.
​Throughout his career, Dr. Yeh has held pivotal roles at Wonder Biotek (DaChan Great Wall Group), United Biomedical Asia, and the National Health Research Institutes (NHRI). His expertise spans the full lifecycle of product development, from high-throughput screening and viral vector vaccine development to the establishment of GMP-compliant facilities and CMC (Chemistry, Manufacturing, and Controls) regulatory strategies. Notably, he has spearheaded the development of recombinant adenoviral vaccine platforms and led technology transfers for international CMO projects.
​Dr. Yeh earned his Ph.D. in Life Sciences from the National Defense Medical Center in collaboration with Academia Sinica. He is a widely published researcher with specialized knowledge in innate immunity and viral pathogenesis. His unique combination of technical mastery in bioprocessing and deep understanding of advanced therapy medicinal product (ATMP) regulations ensures the seamless transition of innovative therapies from the lab to clinical manufacturing.